The Sapienza University of Rome, also called simply Sapienza or the University of Rome, and formally the Università degli Studi di Roma "La Sapienza", is a public research university located in Rome, Italy. It is one of the largest European universities by enrollments and one of the oldest in history, founded in 1303.

During the past decade, Universita' La Sapienza conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 26 clinical trials were completed, i.e. on average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 17 clinical trials were completed. i.e. 141.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universita' La Sapienza" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 9 trials, followed by "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 7 trials sponsored, "University of Roma La Sapienza" with 7 trials sponsored, "International Extranodal Lymphoma Study Group (IELSG)" with 6 trials sponsored and "Boehringer Ingelheim" with 6 trials sponsored. Other sponsors include 52 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universita' La Sapienza" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 2 trials as a collaborator, "Cystic Fibrosis Foundation" with 2 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 2 trials as a collaborator, "A.O. Ospedale Papa Giovanni XXIII" with 1 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Universita' La Sapienza" are "Leukemia" (6 trials), "Cystic Fibrosis" (3 trials), "Multiple Myeloma" (3 trials), "Coronary Artery Disease" (2 trials) and "Diffuse Large B-Cell Lymphoma" (2 trials). Many other conditions were trialed in "Universita' La Sapienza" in a lesser frequency.

Most popular intervention types in "Universita' La Sapienza" are "Drug" (58 trials), "Other" (12 trials), "Biological" (7 trials), "Procedure" (7 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Rituximab" (4 trials), "Ataluren" (3 trials), "cytarabine" (3 trials) and "etoposide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universita' La Sapienza" are 83 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Universita' La Sapienza". 1 are not yet recruiting, 5 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 54 completed trials in Universita' La Sapienza, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Universita' La Sapienza, 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 8 trials that are defined as “Not Applicable".